Document:

Exhibit 10.25

 

EXECUTIVE
EMPLOYMENT AGREEMENT

 

THIS
AGREEMENT is made the __2nd____ day of March, 2022,

 

BETWEEN:

 

BRIACELL
THERAPEUTICS CORP

(the
“Company”)

 

-and-

 

GADI
LEVIN

(the
“Executive”)

 

WHEREAS
the Executive is currently a contractor of the Company as its Chief Financial Officer (“CFO”) and has been since
February 1, 2016 (the “Hire Date”);

 

AND
WHEREAS the Company and the Executive wish to enter into this Agreement to formalize the terms reached between them governing the
Executive’s continued employment with the Company from and after January 1, 2022 (the “Effective Date”) and
which will supersede and replace all prior agreements between the Executive and the Company with respect to the Executive’s employment;

 

NOW
THEREFORE in consideration of the covenants in this Agreement and for other consideration, including an enhanced annual base salary,
the receipt and sufficiency of which are hereby acknowledged by the parties, the parties agree as follows:

 

Article
I

EMPLOYMENT

 

1.01       Position

 

The
Company will continue to employ the Executive in the position of CFO of the Company.

 

1.02       Duties

 

The
Executive will continue to report to the Company’s Chief Executive Officer (“CEO”)
or such other officers as may be determined from time to time by the Company, and will have the duties and responsibilities commensurate
with the position of CFO of a comparable corporation. The Executive will perform additional duties, consistent with the position, as
requested by the CEO or designate from time to time, without additional compensation. The Executive acknowledges that the nature of the
Executive’s position and duties will require frequent travel and performance of work at irregular times, acting reasonably.

 

1.03       Effective
Date

 

The
terms of this Agreement will take effect on the Effective Date and will continue until terminated hereunder. Notwithstanding the foregoing,
the Company will recognize the Executive’s prior service with the Company, which commenced on the Hire Date, for all purposes.

 

    	 

    	- 2 -

    

 

 

Article
II

ASSIGNMENT

 

2.01       Director
and Officer

 

If
requested by the Company, the Executive will agree to serve as a Director and/or Officer of the Company or its subsidiaries and affiliates,
without additional compensation.

 

Article
III

REMUNERATION

 

3.01       Base
Salary

 

Upon
the Effective Date and conditional on the Executive signing this Agreement, the Executive’s annual base salary will increase to
USD$200,000.00 (the “Base
Salary”) (gross), to be pro-rated for any partial year of employment. The Executive’s Base
Salary will be paid in arrears in approximately equal monthly instalments in accordance with the Company’s payroll practices, and
by the 9th day of the following month, based on the currency rates at each payment date.

 

3.02       Discretionary
Bonus

 

(a)       The
Executive shall be eligible to earn up to (i) 30% of the Executive’s Base Salary and (ii) $100,000 (gross) in Company stock options
(vesting equally over a four year period) per calendar year based on achieving corporate and personal objectives as approved by the Board
and in accordance with the terms of the applicable bonus plan, as may be amended. Within 60 days after the Effective Date, the Company
and the Executive shall mutually agree upon the objectives that the Company and the Executive shall need to meet to earn the discretionary
bonus, or percentage thereof. Thereafter, annual objectives that the Company and the Executive shall need to meet for the Executive to
be eligible to earn a discretionary bonus will be mutually agreed upon, in writing, within 60 days of the start of each calendar year.
The Company shall pay the bonus, if any, on an annual basis, within 60 days after Board approval, subject to the conditions in Section
3.02(b) below.

 

(b)       The
Executive acknowledges that (i) the terms and criterion of the discretionary bonus may change each calendar year at the discretion of
the Company, (ii) the Executive has no expectation that in any calendar year that there will be a discretionary bonus, (iii) the amount
of the discretionary bonus, if any, that the Executive may be awarded may change from calendar year to calendar year, (iv) any discretionary
bonus paid to the Executive does not form part of the Executive’s regular wages, unless minimally required otherwise by the applicable
employment standards legislation. For greater certainty and except as minimally required otherwise by the applicable employment standards
legislation, “actively employed” excludes any period subsequent to the date that is the earlier of:

 

(i)       
if the Executive resigns from employment, the effective date of resignation specified in the written notice of resignation from the Executive;
and

 

(ii)       if
the Executive’s employment is terminated by the Company, the date the minimum statutory notice of termination period, if any, prescribed
by the applicable employment standards legislation ends.

 

For
certainty, the Executive shall have no entitlement to a bonus or damages in lieu thereof in respect of any period that extends beyond
the minimum statutory notice of termination period, if any, prescribed by the applicable employment standards legislation, including
any additional period during which the Executive is, or will be, in receipt of compensation, damages or other entitlements in lieu of
notice of termination, whether under contract or common law.

 

    	 

    	- 3 -

    

  

3.03       Options

 

Within
60 days following the Effective Date, the Executive will be granted 20,000 options in accordance with the terms of Briacell Therapeutics
Corp. stock option plan (the “Plan”) or a sub plan as may be implemented by the Company. Such options will also be
subject to the terms of an option agreement between the Executive and Briacell Therapeutics Corp., or the Company as the case may be,
in accordance with the terms of the Plan, which will include terms limiting the Executive’s entitlements to such options following
the cessation of the Executive’s employment. By signing below, the Executive acknowledges that the Executive has carefully reviewed
the terms of the Plan and understands and agrees to same, including the termination provisions at Section 9 of the Plan.

 

3.04       Benefits

 

The
Executive will continue to be eligible to participate in the Company’s benefit plans generally made available to its employees,
in accordance with the terms of such plans. If the Company adopts any new benefit plans of general application, or if any such plans
are modified or eliminated, the Executive will participate on a basis equivalent to other executive-level employees of the Company. All
plans are governed by their respective terms, as may be amended from time to time.

 

3.05       Vacation

 

The
Executive will be eligible for 4 weeks’ vacation with pay per calendar year, to be taken at a time or times mutually agreeable
to the Executive and the Company, taking into account the Company’s operational needs. Vacation in the last calendar year of employment
will be pro-rated based on the period of time actually worked by the Executive for the Company in that calendar year. The Executive must
take vacation time in the calendar year it is earned. Any vacation time in excess of the statutory minimum amount prescribed by the applicable
employment standards legislation not taken in the calendar year in which it is earned cannot be carried over to subsequent calendar years
and will be forfeited at calendar year-end without any further notice or pay or damages in lieu of notice. At cessation of employment,
the Executive hereby acknowledges and agrees that vacation time taken by the Executive but not yet earned will be considered an advance
and/or overpayment and, subject to the applicable employment standards legislation, will be deducted by the Company from the Executive’s
final pay. If the amount owing is greater than the Executive’s final pay, or not deductible in full or in part under the applicable
employment standards legislation, the Executive agrees to pay to the Company any outstanding amounts not covered by the Executive’s
final pay within thirty (30) calendar days after the Executive’s last day of employment.

 

3.06       Sick
Leave

 

The
Executive shall be entitled to sick leave, according to the provisions of the Sick Pay Law, 1976, subject to presentation of a medical
certificate and provided the Employee did not receive sick pay from the National Insurance Institute and/or any other party. Accrued
sick leave days are not redeemable, and the Executive will not be entitled to any kind of payment for unused sick days.

 

3.07       Convalescence

 

The
Executive will be entitled to convalescence pay according to applicable law.

 

    	 

    	- 4 -

    

 

3.08       Travel
expenses

 

The
Executive will be working from home. Therefore, the Executive shall not be entitled to reimbursement of travel expenses.

 

3.09       Pension
and Severance Scheme

 

The
Executive will be insured in a pension scheme of his choice (the “Pension Scheme”).

 

Contributions
to the Pension Scheme shall be based on the Executive’s Salary, as and shall not include any other benefits and/or additional compensation.
In the event the Executive chooses to insure his Salary in more than one pension program, in any event, the insured salary in all such
programs shall not exceed the Employee’s Salary.

 

Should
the Executive choose to insure his Salary, fully or partially, in a pension fund, the Company will contribute to such fund an amount
equal to 14.83% of the part of the Salary insured in the pension fund: 8.33% for severance payments and 6.5% for pension components.

 

Should
the Executive choose to insure his Salary, fully or partially, in a managers’ insurance policy, the Company will contribute to
such policy an amount equal to 14.83% of the part of the Salary insured in the managers’ insurance policy: 8.33% for severance
payments and 6.5% for both pension component and disability insurance, to cover 75% of the salary insured in the managers’ insurance
policy, subject to the pension component being no less than 5%. In the event that the cost of the disability insurance is higher than
1.5%, the Company will bear such costs, subject to the pension component together with a disability component not exceeding a maximum
cost of 7.5%.

 

In
addition, the Company will deduct from the Executive’s Salary an amount equal to 6% of his Salary, to be contributed to the Pension
Scheme, and the Executive hereby approves said deduction.

 

The
Company’s contribution to the Pension Scheme for severance in the amount of 8.33% of the Salary shall be in lieu of 100% of severance
pay with respect to the Salary.

 

The
Company and the Executive will abide by the terms and conditions detailed in the General Approval of the Minister of Labor regarding
payments by Companies to a pension fund and insurance fund in lieu of severance pay, in accordance with section 14 of the Severance Pay
Law 5723-1963 (the “General Permit”), attached as Appendix A to this Agreement, as updated from time
to time. These terms and conditions bind the parties to this agreement. For the avoidance of doubt, it is hereby clarified that the above
conditions do not derogate from the rights and/or benefits granted to the Executive in accordance with this Agreement.

 

The
Company will waive all rights to the sums it has contributed the Scheme, unless the Executive’s right to severance pay has been
revoked by a judgment by virtue of Section 16 or 17 of the Severance Pay Law, 1963, and to the extent so revoked and/or the Executive
has withdrawn money from the Pension Fund or Insurance Fund other than by reason of an Entitling Event; in such regard “Entitling
Event” means death, disability or retirement.

 

3.10       Study
Fund

 

The
Executive will be entitled to contributions to a study fund of his choice (the “Study Fund”). The Company will make
monthly contributions to the Study Fund of 7.5% of the Salary, but in any case contributions will not exceed the maximum amount exempt
from income tax for such payments. The Executive will contribute a monthly payment of 2.5% of the Salary to the Study Fund by means of
withholding from the Executive’s Salary.

 

    	 

    	- 5 -

    

 

3.11       Expenses

 

Consistent
with its corporate policies as established from time to time, the Company will continue to reimburse the Executive for all expenses the
Executive reasonably and properly incurs in connection with the performance of the Executive’s duties, upon providing the Company
with proper written vouchers or receipts. Any expense anticipated to be in excess of USD$1,000 must be pre-approved by the CEO in writing.

 

Article
IV

COVENANTS OF THE EXECUTIVE

 

4.01       Time
and Attention

 

During
the Executive’s employment, the Executive shall continue to devote the Executive’s 60% of his time and attention exclusively
to the business of the Company and shall well and faithfully serve the Company and shall use the Executive’s best efforts to promote
the interests of the Company. The Executive shall not, without the CEO’s prior written approval (which approval may be unreasonably
withheld), accept any other employment or contract for work, or serve as a director, consultant or partner of any business or other enterprise,
other than the Company, except in the capacity as “passive” investor and only so long as such investment does not require
any active involvement or otherwise affect the conduct of the Executive’s duties hereunder.

 

4.02       Duties
and Responsibilities

 

The
Executive shall continue to duly and diligently perform all the Executive’s duties and shall truly and faithfully account for and
deliver to the Company all money, securities and things of value belonging to the Company which the Executive may from time to time receive
for, from or on account of the Company, including any Confidential Information (or otherwise) as defined below.

 

4.03       Rules
and Regulations

 

The
Executive shall continue to faithfully abide by all applicable laws and all rules and regulations of the Company from time to time in
force which are brought to the Executive’s notice or of which the Executive should reasonably be aware.

 

4.04       Conflict
of Interest

 

The
Executive shall continue to refrain from any situation in which the Executive’s personal interests conflict, or may appear to conflict,
with the Executive’s duties with the Company.

 

    	 

    	- 6 -

    

 

Article
V

RESTRICTIVE COVENANTS

 

5.01       Confidential
Information

 

(a)       In
this Agreement, “Confidential Information” means any confidential information concerning the business and affairs
of the Company or of its affiliates and subsidiaries and their respective directors, officers, employees, agents, partners and suppliers.
Confidential Information will not include: (i) the general skills and experience gained by the Executive during the Executive’s
employment with the Company that the Executive could reasonably have been expected to acquire in similar employment with other companies;
(ii) information publicly known or received by the Executive from a third party unrelated to the Company without a breach of an obligation
of confidentiality; (iii) information the disclosure of which is required to be made by any law or court, provided that before disclosure
is made, notice of the requirement is given to the Company by the Executive where it is within the Executive’s control to provide
such notice, and to the extent possible in the circumstances, the Company is afforded an opportunity to dispute the requirement; and
(iv) information the disclosure of which is permitted pursuant to any applicable regulatory whistleblowing legislation.

 

(b)       The
Executive acknowledges that, by reason of the Executive’s employment with the Company, the Executive has had and will continue
to have access to Confidential Information. The Executive agrees that, during and after the Executive’s employment with the Company,
the Executive shall not disclose to any person, except in the proper course of the Executive’s employment with the Company, or
use for the Executive’s own purposes or for any purposes other than those of the Company, any Confidential Information acquired,
created or contributed to by the Executive.

 

5.02       Intellectual
Property

 

(a)       In
this Agreement, “Intellectual Property” means any domestic and foreign:

 

(i)
patents, inventions, applications for patents and reissues, divisions, continuations, renewals, extensions and continuations-in-part
of patents or patent applications; (ii) proprietary and non-public business information, including inventions, developments, trade secrets,
know-how, methods, processes, designs, technology, technical data, schematics, formulae and client lists, and documentation relating
to any of the foregoing; (iii) works of authorship, copyrights, copyright registrations and applications for copyright registration;
(iv) designs, design registrations, design registration applications and integrated circuit topographies; (v) trade names, business names,
corporate names, domain names, website names and world wide web addresses, common law trade-marks, trade-mark registrations, trade mark
applications, trade dress and logos, and the goodwill associated with any of the foregoing; (vi) computer software and programs (both
source code and object code form), all proprietary rights in the computer software and programs and all documentation and other materials
related to the computer software and programs; and (vii) any other intellectual property and industrial property and moral rights, title
and interest therein, anywhere in the world and whether registered or unregistered or protected or protectable under intellectual property
laws,

 

which
the Executive may solely or jointly conceive or develop or reduce to practice, or cause to be conceived or developed or reduced to practice,
during the period of time the Executive is in the employ of the Company, including the copyright thereon.

 

(b)       The
Executive hereby irrevocably and unconditionally assigns and shall assign all Intellectual Property to the Company and agrees that the
Company shall own all right, title and interest in all Intellectual Property.

 

    	 

    	- 7 -

    

 

 (c)       The
Executive hereby irrevocably and unconditionally waives all moral rights arising under the Copyright Act (Canada) as amended (or
any successor legislation of similar effect), or similar legislation in any applicable jurisdiction, or at common law or otherwise, that
the Executive may have now or in the future with respect to Intellectual Property, including any right the Executive may have to have
the Executive’s name associated with the Intellectual Property or to have the Executive’s name not associated with the Intellectual
Property, any right the Executive may have to prevent the alteration, translation or destruction of the Intellectual Property, and any
rights the Executive may have to control the use of the Intellectual Property in association with any product, service, cause or institution.
The Executive agrees that this waiver may be invoked by the Company, and by any of its authorized agents or assignees, in respect of
any or all of the Intellectual Property.

 

(d)       The
Executive will not be eligible to a Service Invention, as its meaning in the Israeli Patents Law, 1967 (the “Patents Law”),
and such will not be the Executive’s property and the provisions of Article 132 (b) of the Patents Law will not apply to the Executive
and to the Company, in such a manner that even if the Executive shall dispatch a notification to the Company regarding the Service Invention
and even if the Company does not respond within six (6) months – the Company will not be considered, under any circumstances, as
having waived the rights to such invention. Without derogating from the generality of the above stated, the Executive hereby explicitly
waive any right, claim, or demand related to the eligibility for any payment, compensation or royalties related to any Intellectual Property,
including with respect of any claim for consideration regarding Service Invention, under Article 134 of the Patents Law. The Executive
hereby declares that his Salary, and all the rest of the accompanying terms of his employment paid
and/or granted to him by the Company, constitute the full and final consideration for any intellectual property that he is likely to
develop and/or compose and/or achieve by any other means as stated above in this undertaking.

 

(e)       The
Executive further agrees to, promptly, at the request of the Company, take all steps and sign all assignments and other documents as
the Company may reasonably require or consider helpful to effect the assignment and transfer of the Intellectual Property and to protect,
obtain or maintain any patents, copyrights, trade-marks or other proprietary rights in the Intellectual Property.

 

5.03       Non-Solicitation
of Employees and Contractors

 

(a)       The
Executive shall not, in any manner whatsoever, without the Company’s prior written consent (with the Executive recusing himself
in all respects from such consent or influencing such consent), at any time during the Executive’s employment and for twelve (12)
months immediately thereafter, directly or indirectly:

 

(i)       induce
or endeavour to induce any employee or contractor of the Company to terminate his, her or its engagement with the Company, whether or
not such employee or contractor would breach his, her or its contract (written or otherwise) with the Company by doing so; or

 

(ii)       employ
or engage or attempt to employ or engage or assist any person to employ or engage any employee or contractor of the Company.

 

(b)       Any
job postings or recruitment campaigns of general or mass application will not be considered a breach of Section 5.04 provided that such
job postings or recruitment campaigns are not targeted specifically towards employees or contractors of the Company and so long as an
employee or contractor of the Company is not hired as a result thereof.

 

5.04       Non-Solicitation
of Partners

 

(a)       The
Executive shall not, in any manner whatsoever, without the Company’s prior written consent (with the Executive recusing himself
in all respects from such consent or influencing such consent), at any time during the Executive’s employment and for twelve (12)
months immediately thereafter, directly or indirectly, canvass or solicit any Partner for the purpose of either encouraging or enticing
the Partner to discontinue or alter in an adverse manner such Partner’s relationship with the Company or to enter into a business
relationship with any person for any reason competitive with the Company.

 

    	 

    	- 8 -

    

 

(b)       For
the purposes of this Agreement, “Partner” means any person with whom the Company established or had, in the twelve
(12) month period prior to the cessation of the Executive’s employment with the Company, a partnership to evaluate, research, market
or sell any treatment, combination, product or service tested, supplied, sold, licensed or distributed by the Company, provided the Executive
was involved in, or had knowledge of, such partnership.

 

5.05       Non-Interference

 

During
the Executive’s employment and for twelve (12) months immediately thereafter, the Executive shall not, without the Company’s
prior written consent (with the Executive recusing himself in all respects from such consent or influencing such consent), directly or
indirectly, interfere with any projects which, with the Executive’s knowledge, the Company had undertaken or as evidenced by a
written document were about to be undertaken at the effective date of cessation of the Executive’s employment.

 

5.06       Non-Disparagement

 

During
and after the Executive’s employment with the Company, the Executive shall not comment in any adverse fashion on the Company, its
subsidiaries or affiliates, or their directors, officers, agents, shareholders or employees, unless permitted to do so in accordance
with any applicable regulatory whistleblowing legislation or required to do so by law or court order.

 

5.07       Acknowledgements

 

(a)       The
Executive acknowledges and agrees that:

 

(i)       the
Company’s business is carried on in North America, and that the Company is interested in and solicits or canvasses opportunities
throughout North America;

 

(ii)       the
Executive is integral to strategy and planning, which includes exploration regarding corporate opportunities in other countries, beyond
those listed above;

 

(iii)       the
Company’s reputation in the industry and its relationships with its Partners is the result of hard work, diligence and perseverance
on behalf of the Company over an extended period of time;

 

(iv)       the
nature of the Company’s business is such that the on-going relationship between the Company and its Partners is material and has
a significant effect on the ability of the Company to continue to obtain business from its Partners for both long term and new contracts;

 

(v)       in
light of the foregoing, the restrictions in this Article V are reasonable and valid and the Executive waives all defences to the strict
enforcement thereof; and

 

(vi)       any
breach of the covenants in this Article V by the Executive will result in material and irreparable harm to the Company, although it may
be difficult for the Company to establish the monetary value flowing from such harm. The Executive therefore further acknowledges and
agrees that the Company, in addition to being entitled to the monetary damages which flow from the breach, will be entitled to injunctive
relief in a court of appropriate jurisdiction in the event of any breach by the Executive of the covenants in this Article V.

 

    	 

    	- 9 -

    

 

Article
VI

TERMINATION OF EMPLOYMENT

 

6.01       Termination
on the Death of the Executive

 

The
Executive’s employment will terminate automatically upon the Executive’s death, following which the Company will pay to the
Executive’s estate: (a) all the Executive’s regular wages and vacation pay accrued and owing up to and including the date
of death; (b) all eligible expenses that have been incurred by the Executive and remain owing as of the date of death; and (c) any other
minimum statutory entitlement that may be owing to the Executive under the applicable employment standards legislation, without duplication.

 

6.02       Termination
by the Company for Cause

 

The
Company may terminate the Executive’s employment for Cause (as defined below) at any time without working notice or any payment
in lieu of notice period on the following terms.

 

For
the purpose of this Employment Agreement, “Cause” shall mean: (i) the Executive’s breach of trust or a fiduciary duty,
fraud, any act that constitutes or involves a conflict of interest between the Executive and the Company, and any breach by the Executive
of the provisions set forth in Article V attached hereto; (ii) any willful misconduct, willful failure to perform any of the Executive’s
duties hereunder, any violation of the Company’s policies or procedures, as may be in effect from time to time, and any other breach
of this Employment Agreement, which, if capable of cure, was not cured within seven (7) days of written notice by the Company with respect
thereto; (iii) the Executive deliberately or recklessly causing harm to the Company’s business, affairs or reputation; (iv) admission,
indictment or conviction of, or entry of any plea of guilty or nolo contendere by, the Executive for any felony or other criminal act
involving moral turpitude; (v) any other circumstances constituting basis for termination without prior written notice and/or severance
payment under applicable law.

 

(a)       if
the Executive is terminated for any reason that provides the Company with the right to terminate the Executive’s employment without
notice under the Israeli Prior Notice Law, 2001 or for Cause , without any working notice, pay in lieu of working notice, severance pay,
or any other entitlement either by way of anticipated earnings or damages of any kind, except for: (i) the Executive’s regular
wages and vacation pay accrued and owing as of the effective termination; (ii) reimbursement for all eligible expenses that have been
incurred by the Executive but remaining owing as of the effective termination date, upon the Executive’s provision of appropriate
vouchers and receipts; and (iii) any other minimum statutory entitlement that may be owing to the Executive under the applicable employment
standards legislation, without duplication; or

 

6.03       Termination
by the Company without Cause

 

(a)       The
Company may terminate the Executive’s employment at any time without cause upon providing the Executive with only:

 

(i)       the
greater of:

 

(A)       six
(6) months’ working notice or payment of the Executive’s then Base Salary in lieu of working notice (or a combination of
both, in the Company’s discretion); and

 

    	 

    	- 10 -

    

 

(B)       the
minimum amount of working notice or payment of the Executive’s regular wages in lieu of working notice (or a combination of both,
at the Company’s discretion) prescribed by the applicable employment standards legislation, plus statutory severance pay, if any,
prescribed by the applicable employment standards legislation;

 

(ii)       the
parties agree that in the case of Section 6.03(a)(i), the Company will have the discretion to determine whether to provide working notice
or payments in lieu of working notice, or a combination of both. To the extent any payments in lieu are provided, the Company will also
have the discretion to determine whether to provide them as a lump-sum or in installments on the Company’s regular payroll dates,
or a combination of both;

 

(iii)       if
applicable, to the extent working notice is provided under Section 6.03 (a)(i)(A), any minimum statutory severance pay as prescribed
by the applicable employment standards legislation at the end of such working notice period in order for the Company to be compliant
with the minimum requirements of the applicable employment standards legislation;

 

(iv)       the
benefit plan contributions necessary to maintain the Executive’s participation for the minimum statutory notice period prescribed
by the applicable employment standards legislation in all benefit plans provided to the Executive by the Company immediately before the
termination of the Executive’s employment. The Executive agrees that the Company may deduct from any payment hereunder the Executive’s
contributions to the benefit plans which were regularly made during the term of this Agreement and the Executive’s employment in
accordance with the such benefit plans;

 

(v)       all
regular wages accrued and owing up to and including the effective termination date;

 

(vi)       all
outstanding vacation pay (including any vacation pay that accrues over the minimum statutory notice period prescribed by the applicable
employment standards legislation);

 

(vii)       reimbursement
for all eligible expenses that have been incurred by the Executive and remain owing as of the effective termination date upon the Executive’s
provision of appropriate vouchers and receipts;

 

(viii)       any
other minimum statutory entitlement that may be owing to the Executive under the applicable employment standards legislation, without
duplication.

 

6.04       Resignation
following a Change of Control

 

(a)       If
within six (6) months following a Change of Control (as defined below), the Executive’s employment is terminated by the Company
without cause, the Company will provide the Executive with only the following in lieu of entitlements under Section 6.03 above:

 

(i)       an
amount equivalent to eighteen (18) months of the Executive’s then Base Salary, to be paid as a lump-sum or via salary continuation
(or a combination of both) in the Company’s discretion; and

 

(ii)       the
other payments and entitlements set out in Section 6.03(a) (iv), (v), (vi),(vii) and (viii).

 

(b)       For
purposes of this Section 6.04, the following terms are defined as:

 

(i)       “Change
of Control” means any of the following:

 

(A)       any
change in ownership, direct or indirect, of shares of the Company and/or securities (“Convertible Securities”) convertible
into, exchangeable for or representing the right to acquire shares of the Company, as a result of or following which an Acquiror (as
defined below) beneficially owns, directly or indirectly, or exercises control or direction over, shares of the Company and/or Convertible
Securities such that, assuming only the conversion, exchange or exercise of Convertible Securities beneficially owned by the Acquiror,
the Acquiror would beneficially own, directly or indirectly, or exercise control or direction over, shares of the Company that would
entitle the holders thereof to cause more than 50% of the votes attaching to all shares of the Company that may be cast to elect directors
of the Company;

 

    	 

    	- 11 -

    

 

(B)       the
acquisition by an Acquiror of all or substantially all of the assets of the Company;

 

(C)       where
the members of the Board of Directors immediately prior to any twelve (12) month period do not constitute a majority of the directors,
trustees or other governing body of the company, corporation, trust or other entity at the end of that same twelve (12) month period;
or

 

(D)       a
merger of the Company with or into one or more other companies, corporations, trusts or other entities (other than subsidiaries of, or
trusts or other entities controlled by the Company):

 

(1)       where
the members of the Board of the Company immediately prior to the consummation of the merger do not constitute a majority of the directors,
trustees or other governing body of the company, corporation, trust or other entity surviving or continuing from the merger;

 

(2)       that
results in the security holders of the parties to the merger other than the Company owning, directly or indirectly, securities of the
company, corporation, trust or other entity surviving or continuing from the merger that entitle the holders thereof to cast more than
50% of the votes attaching to all securities of the surviving or continuing company, corporation, trust or other entity that may be case
to elect its directors, trustees or other governing body; or

 

(3)       that
has been designated by resolution of the directors of the Company as a Change of Control prior to the consummation of the mergers.

 

(ii)       “Acquiror”
means:

 

(A)       a
person, group of persons or persons acting jointly or in concert, or persons associated or affiliated within the meaning of Ontario’s
Securities Act, as may be amended from time to time including any successor legislation, with any such person, group of
persons or persons acting jointly or in concert; and

 

(B)       the
expressions “change in ownership”, “acquisition” and “merger” include, as the context may require,
a transaction or series of transactions by way of takeover bid, purchase, exchange, lease, statutory amalgamation, statutory merger,
reorganization, consolidation, statutory arrangement, recapitalization, liquidation or other business combination.

 

6.05       Voluntary
Resignation

 

If
the Executive wishes to voluntarily resign, the Executive shall provide 8 weeks’ notice in writing to the Company. The Company
may waive such notice in whole or in part and assign transitional duties or require the Executive to work at home or another location
(acting reasonably) by paying the Executive’s regular wages and vacation pay and continuing the Executive’s group benefits
coverage to the effective date of resignation. The Executive agrees that the Company may deduct from any payments hereunder the Executive’s
benefit plan contributions which were regularly made during the term of this Agreement and the Executive’s employment in accordance
with the benefit plans’ terms. The Executive also agrees that the Company’s wavier or reassignment of duties and/or location
will not constitute a termination of the Executive’s employment by the Company or a constructive dismissal at common law.

 

    	 

    	- 12 -

    

 

6.06       Effect
of Cessation of Employment

 

The
Executive agrees that, upon cessation of the Executive’s employment, the Executive will be deemed to have immediately resigned
any position that the Executive may have as an officer or director of the Company together with any other office, position or directorship
which the Executive may hold in any of the Company’s subsidiaries and affiliates. In such event, the Executive shall, at the request
of the Company, promptly sign all documents appropriate to evidence such resignations. The Executive shall not be entitled to any payments
or damages in respect of these resignations in addition to those provided for herein.

 

6.07       Treatment
of Equity Incentives on Termination

 

Upon
the cessation the Executive’s employment with the Company for any reason and except as stated otherwise in this Agreement, any
equity incentives held by the Executive will be dealt with in accordance with the terms and conditions of the applicable plan or program
documents then in effect and the applicable grant agreements, which will include terms limiting the Executive’s entitlements following
the cessation of the Executive’s employment.

 

6.08       Release

 

The
Executive acknowledges and agrees that the entitlements that are provided under this Article VI are reasonable and will be in full satisfaction
of all terms of the cessation of the Executive’s employment, including any entitlement to statutory termination pay and statutory
severance pay under the applicable employment standards legislation, and the Executive will have no other entitlement (including to anticipated
earnings or damages of any kind), whether under statute, contract, common law or otherwise. As a condition precedent to receiving any
entitlement under this Article VI that exceeds the Executive’s minimum statutory entitlements under the applicable employment standards
legislation, the Executive agrees to deliver to the Company before any receipt of such entitlement, a fully executed full and final release
from all actions or claims (save any action or claim that cannot be released by operation of statute) in favour of the Company, its affiliates,
subsidiaries, and its and their directors, officers, employees, shareholders and agents, in a form reasonably satisfactory to the Company
and within the timelines specified by the Company.

 

6.09       Return
of Property

 

Upon
the cessation of the Executive’s employment, or earlier if requested by the Company, and as a condition of the Company providing
the Executive with any entitlements required under this Article VI that exceed the Executive’s minimum statutory entitlements as
prescribed by the applicable employment standards legislation, the Executive shall promptly deliver or caused to be delivered to the
Company all documents, effects, money, Confidential Information or other property belonging to the Company or for which the Company is
liable to others, which are in the possession, charge, control or custody of the Executive.

 

    	 

    	- 13 -

    

 

Article
VII

CONTRACT PROVISIONS

 

7.01       No
Breach of Obligations to Others

 

The
Executive represents to the Company that in carrying out the Executive’s duties for the Company, the Executive shall not disclose
to the Company any confidential information of any third party. The Executive also represents to the Company that the Executive has not
brought to the Company, nor shall the Executive use in the performance of the Executive’s duties with the Company, any confidential
materials or property of any third party. The Executive also represents that the Executive is not a party to any agreement with or under
any legal obligation to any third party that conflicts with any of the Executive’s obligations to the Company under this Agreement.

 

7.02       Survival

 

Upon
cessation of the Executive’s employment, Section 7.02 together with the terms of this Agreement that impose obligations upon the
Executive that extend beyond the cessation of the Executive’s employment will survive and can be enforced by the Company in a court
of competent jurisdiction.

 

7.03       Privacy

 

The
Executive understands and consents to the fact that the Company and its subsidiaries or affiliates may collect, use, store or disclose
personal information about the Executive or any of the Executive’s dependents or beneficiaries (“Employee
Personal Information”) as required for those purposes necessary for, or beneficial to, the conduct
of the employment relationship (including benefits administration). The Executive also understands that the Company may disclose the
Employee Personal Information to a third party administrator for the purpose of administering the Executive’s employment relationship
with the Company or to service providers (such as legal, finance and accounting, information technology and human resources advisors
and/or similar consultants and advisors), law enforcement or government authorities, as necessary to comply with legal requirements or
in the course of a legal action, and to legitimate recipients of communications under applicable laws, where required by law or necessary
for the purpose of, or in connection with, any legal proceedings. By signing below, the Executive hereby consents to such disclosure.

 

7.04       Independent
Advice

 

The
Executive confirms that the Executive has had a reasonable opportunity to obtain independent advice about this Agreement and that the
Executive is signing this Agreement freely and voluntarily with full understanding of its contents.

 

7.05       Governing
Law

 

This
Agreement will be governed by the laws of Israel.

 

7.06       Attornment

 

For
the purpose of all legal proceedings, this Agreement will be deemed to have been performed in Israel and the courts of Israel will have
the exclusive jurisdiction to entertain any action arising under this Agreement. The Executive and the Company each hereby attorns to
the jurisdiction of the courts of Israel, provided that nothing in this Agreement will prevent the Company from proceeding at its election
against the Executive in the courts of any other province or country.

 

7.07       Applicable
Employment Standards Legislation

 

Nothing
in this Agreement is intended to conflict with the applicable employment standards legislation. In the event the applicable employment
standards legislation provides superior statutory entitlements that the terms provided for under this Agreement, the Company shall provide
the Executive with the Executive’s statutory entitlements in substitution for the terms under this Agreement.

 

    	 

    	- 14 -

    

 

7.08       Entire
Agreement

 

This
Agreement, together with the documents referred to herein, constitutes the whole agreement of the parties with reference to the Executive’s
employment with the Company, and it cancels and replaces all prior understandings and agreements between the Executive and the Company,
including the prior consulting agreement dated November 1, 2016.

 

7.09       Pre-Contractual
Representations

 

The
Executive hereby waives any right to assert any claim based on any pre-contractual representations, negligent or otherwise, made by the
Company or its representatives, including with respect to the term as of the Hire Date and the Effective Date.

 

7.10       Change
in Terms and Conditions

 

The
Executive agrees that the terms of this Agreement will govern the Executive’s employment with the Company, regardless of the length
of the Executive’s employment or any changes to the Executive’s terms of employment, and regardless of whether any such change
is material or otherwise.

 

7.11       Severability

 

If
any provision in this Agreement is determined to be void or unenforceable in whole or in part, it will not be deemed to affect or impair
the validity of any other provision of this Agreement herein and each such provision is deemed to be separate and distinct.

 

7.12       Notice

 

Any
notice required or permitted to be given under this Agreement will be in writing and provided to:

 

(a)       in
the case of the Company:

 

3rd
Floor, Bellevue Centre

235-15th
Street

West
Vancouver, British Columbia

V7T
2X1

Attention:
Dr. William V. Williams

Email:
williams@briacell.com

 

(b)       in
the case of the Executive:

 

Harimon
108

Lev
Hasharon

4582500

Israel

Email:
GLevin@briacell.com

 

provided
that a party may from time to time notify the other in writing of a new address to which notices to it shall, after the date of that
notice, be sent until further notice in writing be given. Any notice will be deemed to be effective (i) if personally delivered, on the
date of receipt, (ii) if mailed, on the fifth business day (excluding Saturdays, Sundays and applicable statutory holidays) following
the date of mailing. Despite the above, if a strike or lockout of postal employees is in effect, or generally known to be impending,
notice will be effective only by personal delivery; or (iii) if emailed, or sent by other form of electronic transmission, prior to 5:00
p.m. (Toronto time) on a business day, then on such business day or, if sent on a day that is not a business day or after 5:00 p.m. (Toronto
time) on a business day, then on the next business day.

 

    	 

    	- 15 -

    

 

7.13       Amendments
and Waiver

 

No
modification of or amendment to this Agreement shall be valid or binding unless set out in writing and duly signed by the Company and
no waiver of any breach of any term or provision of this Agreement shall be effective or binding unless made in writing and signed by
the party purporting to give the same and, unless otherwise provided, shall be limited to the specific breach waived.

 

7.14       Assignment

 

This
Agreement, and the rights granted and the obligations incurred hereunder are not assignable, whether in whole or in part, by the Executive
without the prior written consent to such effect of the Company. The Company may assign this Agreement to any of its affiliates or subsidiaries
or to any successor (whether direct or indirect, by purchase, amalgamation, arrangement, merger, consolidation or otherwise) to all or
substantially all of the business or assets of the Company. The Executive, by the Executive’s signature below, expressly consents
to such assignment and, provided that such successor agrees to assume and be bound by the terms and conditions of this Agreement, all
references to the “the Company” herein shall include its successor.

 

7.15       Successors

 

This
Agreement and all rights of the Executive hereunder shall enure to the benefit of and be enforceable by the Executive and the Executive’s
personal or legal representatives, heirs, executors, administrators and successors and shall enure to the benefit of and be binding upon
the Company, its successors and assigns.

 

7.16       Taxes
and Deductions

 

All
payments under this Agreement shall be subject to applicable deductions and withholdings. The Executive will bear all governmental taxes
and other payments which every employee is required to pay according to law.

 

7.17       Counterparts

 

This
Agreement may be executed in counterparts, including via PDF, each of which shall be deemed to be an original but all of which together
shall constitute one and the same instrument.

 

7.18       Copy
of Agreement

 

The
Executive acknowledges receipt of a copy of this Agreement duly signed by the Company.

 

[Signature
page follows]

 

    	 

    	- 16 -

    

 

IN
WITNESS WHEREOF, the parties have executed this Agreement as of the day and year first above written.

 

	 	BRIACELL
    THERAPEUTICS CORP. 
	 	 	 
	 	Per:	 /s/
    William V. Williams
	 	Name:	Dr. William V. Williams
	 	Title:	Chief Executive Officer
	 	I have authority to bind the corporation

 

	 

    SIGNED
    in the presence of:

     
		 

     

	 	/s/
    Gadi Levin
	Witness

    Name:
	 	GADI
    LEVIN

 

    	 

    	- 17 -

    

 

Appendix
A

 

GENERAL
APPROVAL REGARDING PAYMENTS BY COMPANYS TO A PENSION FUND AND INSURANCE FUND IN LIEU OF SEVERANCE PAY

 

By
virtue of my power under section 14 of the Severance Pay Law, 1963 (hereinafter: the “Law”), I certify that payments
made by an Company commencing from the date of the publication of this approval publication for its employee to a comprehensive pension
benefit fund that is not an insurance fund within the meaning thereof in the Income Tax (Rules for the Approval and Conduct of Benefit
Funds) Regulations, 1964 (hereinafter: the “Pension Fund”) or to managers insurance including the possibility of an
insurance pension fund or a combination of payments to an annuity fund and to a non-annuity fund (hereinafter: the “Insurance
Fund”), including payments made by him by a combination of payments to a Pension Fund and an Insurance Fund, whether or not
the Insurance Fund has an annuity fund (hereinafter: the “Company’s Payments”), shall be made in lieu of the
severance pay due to the said employee in respect of the salary from which the said payments were made and for the period they were paid
(hereinafter: the “Exempt Salary”), provided that all the following conditions are fulfilled:

 

		(1)	The
                                            Company’s Payments -

 

(a)
To the Pension Fund are not less than 141/3% of the Exempt Salary or 12% of the Exempt Salary if the Company pays
for its employee in addition thereto also payments to supplement severance pay to a benefit fund for severance pay or to an Insurance
Fund in the employee’s name in an amount of 21/3% of the Exempt Salary. In the event the Company has not
paid an addition to the said 12%, its payments shall be only in lieu of 72% of the employee’s severance pay;

 

(b)
To the Insurance Fund are not less than one of the following:

 

(i)
131/3% of the Exempt Salary, if the Company pays for its employee in addition thereto also payments to secure monthly
income in the event of disability, in a plan approved by the Commissioner of the Capital Market, Insurance and Savings Department of
the Ministry of Finance, in an amount required to secure at least 75% of the Exempt Salary or in an amount of 21/2%
of the Exempt Salary, the lower of the two (hereinafter: “Disability Insurance”);

 

(ii)
11% of the Exempt Salary, if the Company paid, in addition, a payment to the Disability Insurance, and in such case the Company’s
Payments shall only replace 72% of the Employee’s severance pay; In the event the Company has paid in addition to the foregoing
payments to supplement severance pay to a benefit fund for severance pay or to an Insurance Fund in the employee’s name in an amount
of 21/3% of the Exempt Salary, the Company’s Payments shall replace 100% of the employee’s severance
pay.

 

		(2)	No
                                            later than three months from the commencement of the Company’s Payments, a written
                                            agreement is executed between the Company and the employee in which -

 

(i)
The employee has agreed to the arrangement pursuant to this approval in a text specifying the Company’s Payments, the Pension Fund
and Insurance Fund, as the case may be; the said agreement shall also include the text of this approval;

 

(ii)The
Company waives in advance any right, which it may have to a refund of monies from its payments, unless the employee’s right to
severance pay has been revoked by a judgment by virtue of Section 16 or 17 of the Law, and to the extent so revoked and/or the employee
has withdrawn monies from the Pension Fund or Insurance Fund other than by reason of an entitling event; in such regard “Entitling
Event” means death, disability or retirement at or after the age of 60.

 

		(3)	This
                                            approval is not such as to derogate from the employee’s right to severance pay pursuant
                                            to any law, collective agreement, extension order or employment agreement, in respect of
                                            salary over and above the Exempt Salary.

 

	 	 	/s/
    Gadi Levin
	Company	 	ExecutiveExhibit
10.26

 

EMPLOYMENT
AGREEMENT

 

THIS
AGREEMENT is entered into April 16, 2021 and is effective as of May 26, 2021 by and between BriaCell Therapeutics Corp., a Delaware corporation
having an address at 820 Heinz Ave., Berkeley, CA 94710 (the “Company”), and Miguel Lopez-Lago, Ph.D. (“Employee”).

 

W
I T N E S S E T H: 

 

WHEREAS,
the Company desires to employ Employee, and Employee is willing to accept such employment, all on the terms and subject to the conditions
hereinafter set forth.

 

NOW,
THEREFORE, in consideration of the terms and conditions hereinafter set forth, the parties hereto agree as follows:

 

1.
Engagement

 

(a)
Position and Duties. The Company agrees to employ Employee in the position of Senior Director, Research and Development, and Employee
shall perform the duties and functions as are normally carried out by a Senior Director, Research and Development of a developer of pharmaceutical
or biotechnology company of a size comparable to the Company that has a class of equity securities registered under Section 12 of the
Securities Exchange Act of 1934, as amended. Without limiting the generality of the immediately preceding sentence, Employee’s
duties shall include, but shall not be limited to: (i) developing and executing all research and development activities of the Company,
including supervision and training of research staff, (ii) securing research grants; (iii) accomplishing the tasks outlined in awarded
grants, as applicable, (iv) assisting with setting up policies, procedures, and controls to comply with good laboratory practices; and
(v) other administrative duties as assigned by the Company, which could be altered or changed from time to time (see Appendix A). Employee
shall devote Employee’s best efforts, skills and abilities, on a full-time basis, exclusively to the Company’s business pursuant
to, and in accordance with, reasonable business policies and procedures, as fixed from time to time by the Board of Directors of the
Company. Employee covenants and agrees to faithfully adhere to and fulfill such policies as are established from time to time by the
Company’s management and by the Board of Directors. Employee will report to the President and Chief Executive Officer of the Company.

 

(b)
No Conflicting Obligations. Employee represents and warrants to the Company that Employee is under no obligations or commitments,
whether contractual or otherwise, that are inconsistent with Employee’s obligations under this Agreement or that would prohibit
Employee, contractually or otherwise, from performing Employee’s duties as Senior Scientist, Research and Development of the Company
as provided in this Agreement.

 

(c)
No Unauthorized Use of Third-Party Intellectual Property. Employee represents and warrants that Employee will not use or disclose,
in connection with Employee’s employment by the Company, any patents, trade secrets, confidential information, or other proprietary
information or intellectual property as to which any other person has any right, title, or interest, except to the extent that the Company
holds a valid license or other written permission for such use from the owner(s) thereof. Employee represents and warrants to the Company
that Employee has returned all property and confidential information belonging to any prior employer.

 

    	-1-

     

    

 

2.
Compensation

 

(a)
Salary. During the term of this Agreement, the Company shall pay to the Employee an annual salary of One-Hundred Seventy-Thousand
dollars ($170,000) the (“Annual Salary”). Employee’s salary shall be paid in equal semi-monthly installments, consistent
with the Company’s regular salary payment practices. Employee’s salary may be increased from time to time by the Company
without affecting this Agreement. The Employee will also receive a one-time signing bonus of Ten Thousand dollar ($10,000).

 

(b)
Bonus Plans. Employee shall be eligible for certain bonus payments based on the successful completion of certain corporate milestones
and as agreed upon with management of the Company. Such bonus plans shall be developed on an annual basis and monitored by the Company.
Bonus payments shall be made to Employee within sixty (60) days of achievement of milestone.

 

(c)
Expense Reimbursements. The Company shall reimburse Employee for reasonable travel and other business expenses incurred by
Employee in the performance of Employee’s duties hereunder, subject to the Company’s (or a subsidiary’s) policies and
procedures in effect from time to time, and provided that Employee submits supporting vouchers.

 

(d)
Benefit Plans. Employee shall be eligible (to the extent Employee qualifies) to participate in any retirement, pension, life,
health, accident, and disability insurance, stock option plan, or other similar employee benefit plans which may be adopted by the Company.

 

(e)
Stock Options. The Company will grant Employee an option to purchase Ten Thousand (10,000) of the Company’s common shares,
no par value (the “Option”). The exercise price of the Option will be the last closing price of the Company’s common
shares immediately prior to approval of this grant by the Compensation Committee of the Company’s Board of Directors. The Options
will be granted in a lump sum after 6 months of Employee’s continued employment with the Company. The unvested portion of the Option
shall not be exercisable. The Option will not be transferable by Employee during Employee’s lifetime, except as provided in the
Stock Option Agreement.

 

(f)
Vacation; Sick Leave. Employee shall be entitled to three weeks (i.e., 15 business days) of vacation/sick leave without reduction
in compensation, during each calendar year. Such vacation/sick leave shall be taken at such time as is consistent with the needs and
policies of the Company. All vacation days and sick leave days shall accrue annually based upon days of service. Unused vacation days
and sick leave days remaining at the end of the Company’s fiscal year will not be carried over into subsequent fiscal years.

 

    	-2-

     

    

 

3.
Competitive Activities. During the term of Employee’s employment with the Company and for one year thereafter, Employee shall
not, for Employee’s own self or any third party, directly or indirectly employ, solicit for employment, or recommend for employment
any person employed by the Company. During the term of Employee’s employment, Employee shall not, directly or indirectly as an
employee, contractor, officer, director, member, partner, agent, or equity owner, engage in any activity or business that competes or
could reasonably be expected to compete with the business of the Company. Employee acknowledges that there is a substantial likelihood
that the activities described in this Section would (a) involve the unauthorized use or disclosure of the Company’s Confidential
Information and that use or disclosure would be extremely difficult to detect, and (b) result in substantial competitive harm to the
business of the Company. Employee has accepted the limitations of this Section as a reasonably practicable and unrestrictive means of
preventing such use or disclosure of Confidential Information and preventing such competitive harm.

 

4.
Inventions/Intellectual Property/Proprietary Information

 

(a)
Inventions and Discoveries Belong to the Company. Any and all inventions, discoveries, improvements, or intellectual property
relating to or in any way pertaining to or connected with the systems, products, apparatus, or methods employed, manufactured, constructed,
or researched by the Company which Employee may conceive or make while performing services for the Company (“Intellectual Property”)
shall be the sole and exclusive property of the Company. Employee hereby irrevocably assigns and transfers to Company all rights, title
and interest in and to all Intellectual Property that Employee may now or in the future have under patent, copyright, trade secret, trademark
or other law, in perpetuity or for the longest period otherwise permitted by law, without the necessity of further consideration. The
Company will be entitled to obtain and hold in its own name all copyrights, patents, trade secrets, trademarks and other similar registrations
with respect to such Intellectual Property.

 

(i)
The obligations provided for by this Agreement, except for the requirements as to disclosure in Section 4(b), do not apply to any
rights Employee may have acquired in connection with Intellectual Property for which no equipment, supplies, facility, or trade secret
information of the Company was used and which was developed entirely on the Employee’s own time and (a) which at the time of conception
or reduction to practice does not relate directly or indirectly to the business of the Company, or to the actual or demonstrable anticipated
research or development activities or plans of the Company, or (b) which does not result from any work performed by Employee for the
Company. All Intellectual Property that (1) results from the use of equipment, supplies, facilities, or trade secret information of the
Company; (2) relates, at the time of conception or reduction to practice of the invention, to the business of the Company, or actual
or demonstrably anticipated research or development of the Company; or (3) results from any work performed by the Employee for the Company
shall be assigned and is hereby assigned to the Company. If Employee wishes to clarify that something created by Employee prior to Employee’s
employment by the Company that relates to the actual or proposed business of the Company is not within the scope of this Agreement, Employee
has listed it on Exhibit B in a manner that does not violate any third-party rights.

 

To
the extent allowed by law, the rights assigned by Employee to the Company includes all rights of paternity, integrity, disclosure and
withdrawal, and any other rights that may be known as or referred to as “moral rights,” “artist’s rights,”
“droit moral,” or the like (collectively “Moral Rights”). To the extent Employee retains any such Moral Rights
under applicable law, Employee hereby ratifies and consents to any action that may be taken with respect to such Moral Rights by or authorized
by the Company and agrees not to assert any Moral Rights with respect thereto. Employee shall confirm in writing any such ratifications,
consents, and agreements from time to time as requested by the Company.

 

    	-3-

     

    

 

Employee
agrees to execute and sign any and all applications, assignments, or other instruments which the Company may deem necessary in order
to enable the Company, at its expense, to apply for, prosecute, and obtain patents of the United States or foreign countries for the
Intellectual Property, or in order to assign or convey to, perfect, maintain or vest in the Company the sole and exclusive right, title,
and interest in and to said improvements, discoveries, inventions, or patents. If the Company is unable after reasonable efforts to secure
Employee’s signature, cooperation or assistance in accordance with the preceding sentence, whether because of Employee’s
incapacity or any other reason whatsoever, Employee hereby designates and appoints the Company or its designee as Employee’s agent
and attorney-in-fact, to act on his behalf, to execute and file documents and to do all other lawfully permitted acts necessary or desirable
to perfect, maintain or otherwise protect the Company’s rights in the Intellectual Property. Employee acknowledges and agrees that
such appointment is coupled with an interest and is irrevocable.

 

(b)
Disclosure of Inventions and Discoveries. Employee agrees to disclose promptly to the Company all improvements, discoveries,
or inventions which Employee may make solely, jointly, or commonly with others. Employee agrees to assign and hereby assigns all right,
title and interest in any such improvements, discoveries, inventions, or intellectual property to the Company, where the rights are the
property of the Company. This paragraph is applicable whether or not the Intellectual Property was made under the circumstances described
in paragraph (a) of this Section.

 

Employee
agrees to make such disclosures understanding that they will be received in confidence and that, among other things, they are for the
purpose of determining whether or not rights to the related invention, discovery, improvement, or intellectual property is the property
of the Company.

 

(c)
Confidential and Proprietary Information. During this employment with the Company, Employee will have access to trade secrets
and confidential information of the Company. Confidential Information means all information and ideas, in any form, relating in any manner
to matters such as: products; formulas; technology and know-how; inventions; clinical trial plans and data; business plans; marketing
plans; the identity, expertise, and compensation of employees and contractors; systems, procedures, and manuals; customers; suppliers;
joint venture partners; research collaborators; licensees; and financial information. Confidential Information also shall include any
information of any kind, whether belonging to the Company or any third party, that the Company has agreed to keep secret or confidential
under the terms of any agreement with any third party. Confidential Information does not include: (i) information that is or becomes
publicly known through lawful means other than unauthorized disclosure by Employee; (ii) information that was rightfully in Employee’s
possession prior to this employment with the Company and was not assigned to the Company or was not disclosed to Employee in Employee’s
capacity as an employee or other fiduciary of the Company; or (iii) information disclosed to Employee, after the termination of this
employment by the Company, without a confidential restriction by a third party who rightfully possesses the information and did not obtain
it, either directly or indirectly, from the Company and who is not subject to an obligation to keep such information confidential for
the benefit of the Company or any third party with whom the Company has a contractual relationship. Employee understands and agrees that
all Confidential Information shall be kept confidential by Employee both during and after this employment by the Company. Employee further
agrees that Employee will not, without the prior written approval by the Company, disclose any Confidential Information, or use any Confidential
Information in any way, either during the term of this employment with the Company or at any time thereafter, except as required by the
Company in the course of this employment.

 

    	-4-

     

    

 

5.
Termination of Employment. Employee understands and agrees that this employment with the Company has no specific term. This Agreement,
and the employment relationship, are “at will” and may be terminated by either party with or without cause upon thirty (30)
days advance written notice to the other. Except as otherwise agreed in writing or as otherwise provided in this Agreement, upon termination
of Employee’s employment, the Company shall have no further obligation to Employee by way of compensation or otherwise as expressly
provided in this Agreement.

 

(a)
Separation Benefits. Upon termination of Employee’s employment with the Company for any reason, Employee will be entitled
to receive payment for all unpaid salary, accrued but unpaid bonus, if any, and vacation accrued as of the date of termination of Employee’s
employment, but Employee will not be entitled to any other compensation, award, or damages with respect to this employment with the Company
or termination of this employment.

 

(b)
Release. Any other provision of this Agreement notwithstanding, paragraph (a) of this Section shall not apply unless the Employee
(i) has executed a general release of all claims (in a form prescribed by the Company) and (ii) has returned all property of the Company
in the Employee’s possession.

 

6.
Turnover of Property and Documents on Termination. Employee agrees that on or before termination of Employee’s employment with
the Company, Employee will return to the Company all equipment and other property belonging to the Company, and all originals and copies
of Confidential Information (in any and all media and formats, and including any document or other item containing Confidential Information)
in Employee’s possession or control, and all of the following (in any and all media and formats, and whether or not constituting
or containing Confidential Information) in Employee’s possession or control: (a) lists and sources of customers; (b) proposals
or drafts of proposals for any research grant, research or development project or program, marketing plan, licensing arrangement, or
other arrangement with any third party; (c) reports, job or laboratory notes, specifications, and drawings pertaining to the research,
development, products, patents, and technology of the Company; and (d) any and all inventions or intellectual property developed by Employee
during the course of employment.

 

7.
Arbitration. Except for injunctive proceedings against unauthorized disclosure of confidential information, any and all claims or
controversies between the Company and Employee, including but not limited to (a) those involving the construction or application of any
of the terms, provisions, or conditions of this Agreement; (b) all contract or tort claims of any kind; and (c) any claim based on any
federal, state, or local law, statute, regulation, or ordinance, including claims for unlawful discrimination or harassment, shall be
settled by arbitration in accordance with the then current Employment Dispute Resolution Rules of the American Arbitration Association.
Judgment on the award rendered by the arbitrator(s) may be entered by any court having jurisdiction thereof. The location of the arbitration
shall be Philadelphia, Pennsylvania. Unless the parties mutually agree otherwise, the arbitrator shall be a retired judge selected from
a panel provided by the American Arbitration Association, or the Judicial Arbitration and Mediation Service (“JAMS”). The
Company shall pay the arbitrators’ fees and costs. Each party shall pay for its own costs and attorneys’ fees, if any. However,
if any party prevails on a statutory claim which affords the prevailing party attorneys’ fees, the arbitrator may award reasonable
attorneys’ fees and costs to the prevailing party.

 

EMPLOYEE
UNDERSTANDS AND AGREES THAT THIS AGREEMENT TO ARBITRATE CONSTITUTES A WAIVER OF EMPLOYEE’S RIGHT TO A TRIAL BY JURY OF ANY MATTERS
COVERED BY THIS AGREEMENT TO ARBITRATE.

 

    	-5-

     

    

 

8.
Severability. In the event that any of the provisions of this Agreement shall be held to be invalid or unenforceable in whole or
in part, those provisions to the extent enforceable and all other provisions shall nevertheless continue to be valid and enforceable
as though the invalid or unenforceable parts had not been included in this Agreement. In the event that any provision relating to the
time period of restriction shall be declared by a court of competent jurisdiction to exceed the maximum time period such court deems
reasonable and enforceable, then the time period of restriction deemed reasonable and enforceable by the court shall become and shall
thereafter be the maximum time period.

 

9.
Agreement Read and Understood. Employee acknowledges that Employee has carefully read the terms of this Agreement, has had an opportunity
to consult with an attorney or other representative of Employee’s own choosing regarding this Agreement, understands the terms
of this Agreement, and is entering this agreement of Employee’s own free will.

 

10.
Complete Agreement, Modification. This Agreement is the complete agreement between the parties on the subjects contained herein and
supersedes all previous correspondence, promises, representations, and agreements, if any, either written or oral. No provision of this
Agreement may be modified, amended, or waived except by a written document signed both by the Company and Employee.

 

11.
Governing Law. This Agreement shall be construed and enforced according to the laws of the State of Pennsylvania.

 

12.
Assignability. This Agreement, and the rights and obligations of the parties under this Agreement, may not be assigned by Employee.
The Company may assign any of its rights and obligations under this Agreement to any successor or surviving corporation, limited liability
company, or other entity resulting from a merger, consolidation, sale of assets, sale of stock, sale of membership interests, or other
reorganization, upon condition that the assignee shall assume, either expressly or by operation of law, all of the Company’s obligations
under this Agreement.

 

13.
Survival. This Section 13 and the covenants and agreements contained in Sections 4 and 6 of this Agreement shall survive termination
of this Agreement and of Employee’s employment.

 

14.
Notices. Any notices or other communication required or permitted to be given under this Agreement shall be in writing and shall
be mailed by certified mail, return receipt requested, or sent by next business day air courier service, or personally delivered to the
party to whom it is to be given at the address of such party set forth on the signature page of this Agreement (or to such other address
as the party shall have furnished in writing in accordance with the provisions of this Section 14).

 

[REMAINEDER
OF PAGE INTENTIALLY LEFT BLANK]

 

    	-6-

     

    

 

IN
WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written.

 

	BRIACELL
    THERAPEUTICS CORP.	 	Miguel
    Lopez-Lago, Ph.D.
	 	 	 
	Per:	/s/
    William V. Williams	 	Per:
    	/s/
    Miguel Lopez-Lago, Ph.D.
	 	William
    V. Williams, MD	 	 
	 	President & CEO	 	 
	 	I
    have authority to bind the Company	 	 

 

    	-7-

     

    

 

Appendix
A: Additional Duties

 

	 	●	Assure
    Good Documentation Practice (GDP) is followed by all laboratory personnel.
	 	 	 
	 	●	Become
    familiar with Good Laboratory Practice (GLP) and Good Manufacturing Practice (GMP), noting that these will not be required at the
    BriaCell research laboratory, but may be required by certain vendors BriaCell will contract with.
	 	 	 
	 	●	Establish
    new (or amend previous) Standing Operating Procedures and Safety Policies, and with support from the BriaCell Regulatory Affairs
    Consultants, in good faith, ensure the laboratory is in full regulatory compliance with appropriate statutes and regulations including
    but not limited to US FDA requirements.
	 	 	 
	 	●	If
    appropriate, establish a computerized laboratory notebook system and make laboratory notebooks accessible to selected persons for
    review as instructed by the President and CEO.

 

    	-8-

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00349-of-00352.parquet"}]]